Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
Ohad Shimshon BenturRonit GurionAnat Gafter-GviliMoshe GattLev ShvidelNetanel A HorowitzRon RamYair HerishanuNadav SaridOra PaltielChezi GanzelNatalia KreinizNajib DallyOdit GutweinPia RaananiIrit AviviChava PerryPublished in: Leukemia & lymphoma (2017)
Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma. Patients with stage I disease are usually treated with radiotherapy (RT). In previous studies, mostly from the pre positron emission tomography-computed tomography (PET-CT) era, the 5 year progression-free survival (PFS) and overall survival (OS) rates of stage I disease were 60-80% and 80-93%, respectively. This study retrospectively evaluated the outcome of stage I FL which was treated with involved field RT in the PET-CT era between 2002 and 2015. Ninety-one patients were enrolled. Five year PFS and OS rates were 73% and 97%, respectively. Relapse occurred in 19 (21%) patients, 74% occurring outside the radiation field. In conclusion, PET-CT staging of clinical stage I FL may contribute to the improved prognosis in patients treated with RT compared to historical cohorts, possibly due to better identification of "genuine" stage I disease.
Keyphrases
- pet ct
- positron emission tomography
- computed tomography
- free survival
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- early stage
- peritoneal dialysis
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- magnetic resonance imaging
- radiation induced
- lymph node
- combination therapy
- replacement therapy